Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Warren

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
British Journal of Clinical Pharmacology|September 30, 2011
Antidepressants and the developing nervous systemJohn B Warren
British Journal of Clinical Pharmacology|November 30, 2016
Composite endpoints and the distortion of risk-benefit analysisJohn B Warren
British Journal of Clinical Pharmacology|April 5, 2019
Translating the dose response into risk and benefitJohn B Warren
The Lancet. Psychiatry|November 8, 2018
Unbalanced risk-benefit analysis of ADHD drugsJohn B Warren
British Journal of Clinical Pharmacology|January 10, 2018
Fatal prescription chartsJohn B Warren
British Journal of Clinical Pharmacology|May 12, 2012
Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?John B Warren
BMJ (Clinical Research Ed.)|September 5, 2020
The trouble with antidepressants: why the evidence overplays benefits and underplays risks-an essay by John B WarrenJohn B Warren
British Journal of Clinical Pharmacology|October 13, 2011
Comment on: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe by Johnston et alJohn B Warren, Kersti Oselin
British Journal of Clinical Pharmacology|July 18, 2017
Opioids out of controlChristopher N Floyd, John B Warren
British Journal of Clinical Pharmacology|March 13, 2012
Symmetrical analysis of risk-benefitJohn B Warren, Simon Day, Peter Feldschreiber
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|September 30, 2011
Antidepressants and the developing nervous systemJohn B Warren
British Journal of Clinical Pharmacology|November 30, 2016
Composite endpoints and the distortion of risk-benefit analysisJohn B Warren
British Journal of Clinical Pharmacology|April 5, 2019
Translating the dose response into risk and benefitJohn B Warren
The Lancet. Psychiatry|November 8, 2018
Unbalanced risk-benefit analysis of ADHD drugsJohn B Warren
British Journal of Clinical Pharmacology|January 10, 2018
Fatal prescription chartsJohn B Warren
British Journal of Clinical Pharmacology|May 12, 2012
Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?John B Warren
BMJ (Clinical Research Ed.)|September 5, 2020
The trouble with antidepressants: why the evidence overplays benefits and underplays risks-an essay by John B WarrenJohn B Warren
British Journal of Clinical Pharmacology|October 13, 2011
Comment on: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe by Johnston et alJohn B Warren, Kersti Oselin
British Journal of Clinical Pharmacology|July 18, 2017
Opioids out of controlChristopher N Floyd, John B Warren
British Journal of Clinical Pharmacology|March 13, 2012
Symmetrical analysis of risk-benefitJohn B Warren, Simon Day, Peter Feldschreiber
Pageof 3